This inventor holds 1 USPTO granted patent. Top assignee: Aktis Oncology, Inc.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Matthew Roden: Innovator in Oncology
Introduction
Matthew Roden is a prominent inventor based in Boston, MA (US). He has made significant contributions to the field of oncology through his innovative work. His expertise and dedication have led to the development of groundbreaking technologies aimed at improving cancer treatment.
Latest Patents
Matthew Roden holds a patent for "B7-H3 Miniproteins, Conjugates, and Uses Thereof." This patent represents a significant advancement in the understanding and treatment of cancer. It showcases his commitment to developing novel therapeutic approaches that can potentially enhance patient outcomes.
Career Highlights
Matthew Roden is currently employed at Aktis Oncology, Inc., where he continues to push the boundaries of cancer research. His work at the company focuses on creating innovative solutions that address critical challenges in oncology. With a strong foundation in research and development, he has established himself as a key player in the field.
Collaborations
Matthew collaborates with talented individuals such as Brian Scott Goodman and Ved Srivastava. These partnerships enhance the research efforts at Aktis Oncology, Inc. and contribute to the advancement of cancer therapies.
Conclusion
Matthew Roden's contributions to oncology through his patent and work at Aktis Oncology, Inc. highlight his role as an influential inventor in the field. His dedication to innovation continues to inspire advancements in cancer treatment.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile